FDA Approves AstraZeneca’s Imfinzi for Limited-Stage Small Cell Lung Cancer
AstraZeneca’s Imfinzi (durvalumab) has been approved in the United States for the treatment of adult patients with limited-stage small cell lung cancer.
Tag: durvalumab Imfinzi
All
Latest
FDA Approves AstraZeneca’s Imfinzi for Limited-Stage Small Cell Lung Cancer
AstraZeneca’s Imfinzi (durvalumab) has been approved in the United States for the treatment of adult patients with limited-stage small cell lung cancer.
Read More
FDA Approves Durvalumab-Chemo Combo for Resectable NSCLC
The approval was based on trial results which showed the regimen reduced the risk of recurrence, progression, or death by 32% versus neoadjuvant chemotherapy alone.
Read More
AstraZeneca’s NSCLC Therapy Imfinzi Misses Primary Endpoint in Ph3 Study
AstraZeneca’s Imfinzi (durvalumab) concurrently administered with chemoradiotherapy did not achieve a Phase 3 primary endpoint of progression-free survival versus CRT alone for the treatment of patients with unresectable, Stage III non-small cell lung cancer.
Read More
FDA Approves AstraZeneca’s Lung Cancer Drugs
AstraZeneca said on Friday its lung cancer drugs Imfinzi and Imjudo have been approved by the U.S. Food and Drug Administration (FDA).
Read More
FDA Clears Imfinzi for Small Cell Lung Cancer
The US FDA cleared Imfinzi, for use with chemo, to treat patients with extensive-stage small cell lung cancer.
Read More
Imfinzi Trial Shows Drug Can Boost Survival Rates in Lung Cancer Patients
Data from a late-stage trial on the cancer drug Imfinzi, in combination with chemotherapies, demonstrated improvement in survival of certain lung cancer patients, AstraZeneca Plc announced this week.
Read MoreFDA Grants Priority Review to Imfinzi for Advanced NSCLC
The FDA granted priority review to durvalumab for the treatment of patients with locally advanced unresectable non-small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy. The...
Read More
FDA Grants Breakthrough Therapy Designation to Imfinzi for Non-small Cell Lung Cancer
Imfinzi (durvalumab) has been granted breakthrough therapy status by the FDA for the treatment of...
Read MoreAstraZenaca Lung Cancer Drug Fails to Reach Ph3 Endpoint
According to multiple media reports, AstraZeneca’s investigational lung cancer therapy missed a key primary endpoint in a Phase 3 “MYSTIC” trial for first-line NSCLC lung cancer patients.
Read More